Novo Nordisk A/S (NYSE:NVO) Trading Down 1.1% – Here’s What Happened

Shares of Novo Nordisk A/S (NYSE:NVO) were down 1.1% on Thursday . The stock traded as low as $36.36 and last traded at $37.0520. Approximately 21,208,057 shares traded hands during mid-day trading, a decline of 15% from the average daily volume of 25,096,703 shares. The stock had previously closed at $37.45.

Novo Nordisk A/S News Summary

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: FDA approved Wegovy® HD (semaglutide 7.2 mg) after the STEP UP trial showed ~20.7% mean weight loss and ~1/3 of patients achieved ≥25% weight loss; approval was accelerated under a national-priority voucher and Novo expects a U.S. launch in April — this materially strengthens Novo’s product mix and ability to compete on efficacy. FDA approves higher dose version of weight loss drug Wegovy as Novo Nordisk tries to win back market share
• Positive Sentiment: Analyst coverage: Sanford C. Bernstein initiated coverage with an “outperform” and a $175 price target, signaling strong investor conviction in long‑term upside if Novo reclaims market share and margins.
• Positive Sentiment: Pipeline boost: Novo reported positive Phase 2 data for investigational triple‑agonist UBT251, adding another potential weight‑loss asset to its pipeline and diversifying risk beyond semaglutide. Novo Nordisk Obesity Drug Data Sparks Questions On Valuation And Momentum
• Positive Sentiment: Clinical adherence argument: a study showing stopping GLP‑1s raises cardiovascular risks supports long‑term, chronic use of therapies like Wegovy — a structural demand argument for sustained sales. Healthy Returns: Stopping GLP-1s raises risk of heart attack, stroke and death, study says
• Neutral Sentiment: Market access expansion: Novo is pushing to broaden Wegovy access in Japan (self‑pay channels), which could add incremental volume but faces regulatory and reimbursement complexity. Novo Nordisk Seeking to Expand Weight-Loss Drugs Access in Japan
• Negative Sentiment: Competitive pressure: Eli Lilly confirmed superior weight‑loss results for next‑gen drug retatrutide, intensifying pricing and share‑loss risk in the obesity market. Eli Lilly Confirms ‘Superior Weight Loss’ Of Its Next-Generation Obesity Drug
• Negative Sentiment: Patent expiry risk: semaglutide patent expiration in India opens the door to low‑cost generics and potential pricing pressure in emerging markets. Novo Nordisk patent expiry opens door to cheaper weight-loss drugs in India
• Negative Sentiment: Sentiment/valuation pressure: shares have declined sharply over the past year and intraday weakness reflects investor doubts about peak market share, pricing competition and near‑term growth visibility. Novo Nordisk (NVO) Declines More Than Market: Some Information for Investors

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the stock. The Goldman Sachs Group reissued a “neutral” rating and issued a $41.00 price objective (down from $63.00) on shares of Novo Nordisk A/S in a research note on Monday, March 2nd. HSBC reiterated a “hold” rating and set a $54.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday, December 10th. TD Cowen cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $42.00 price target for the company. in a report on Tuesday, March 10th. BMO Capital Markets restated a “market perform” rating on shares of Novo Nordisk A/S in a research report on Thursday, February 5th. Finally, Sanford C. Bernstein started coverage on Novo Nordisk A/S in a report on Wednesday. They issued an “outperform” rating and a $175.00 price objective on the stock. Four investment analysts have rated the stock with a Buy rating and nineteen have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $65.56.

Novo Nordisk A/S Price Performance

The company has a debt-to-equity ratio of 0.61, a quick ratio of 0.57 and a current ratio of 0.80. The stock’s fifty day moving average price is $49.07 and its 200-day moving average price is $51.39. The firm has a market cap of $165.44 billion, a PE ratio of 10.68 and a beta of 0.73.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Tuesday, February 3rd. The company reported $1.01 EPS for the quarter, topping analysts’ consensus estimates of $0.90 by $0.11. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. The firm had revenue of $12.43 billion for the quarter, compared to the consensus estimate of $11.97 billion. As a group, equities analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Dividend Announcement

The company also recently disclosed a dividend, which will be paid on Wednesday, April 8th. Investors of record on Monday, March 30th will be paid a $1.2751 dividend. This represents a yield of 541.0%. The ex-dividend date of this dividend is Monday, March 30th. Novo Nordisk A/S’s dividend payout ratio (DPR) is presently 23.63%.

Institutional Trading of Novo Nordisk A/S

A number of institutional investors have recently bought and sold shares of the company. Capital International Investors raised its stake in shares of Novo Nordisk A/S by 52.4% during the 3rd quarter. Capital International Investors now owns 17,713,424 shares of the company’s stock worth $982,969,000 after buying an additional 6,092,192 shares during the last quarter. Loomis Sayles & Co. L P grew its stake in Novo Nordisk A/S by 6.0% in the 4th quarter. Loomis Sayles & Co. L P now owns 17,135,384 shares of the company’s stock valued at $871,848,000 after acquiring an additional 969,916 shares during the last quarter. Franklin Resources Inc. increased its holdings in Novo Nordisk A/S by 5.1% during the 4th quarter. Franklin Resources Inc. now owns 14,702,508 shares of the company’s stock valued at $748,064,000 after acquiring an additional 717,719 shares in the last quarter. Morgan Stanley increased its holdings in Novo Nordisk A/S by 3.5% during the 4th quarter. Morgan Stanley now owns 12,842,089 shares of the company’s stock valued at $653,406,000 after acquiring an additional 428,660 shares in the last quarter. Finally, Folketrygdfondet raised its position in Novo Nordisk A/S by 1.2% during the third quarter. Folketrygdfondet now owns 10,211,913 shares of the company’s stock worth $566,659,000 after acquiring an additional 117,370 shares during the last quarter. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.